Article thumbnail

A Window into the Heterogeneity of Human Cerebrospinal Fluid Aβ Peptides

By Roberta Ghidoni, Anna Paterlini, Valentina Albertini, Elena Stoppani, Giuliano Binetti, Kjell Fuxe, Luisa Benussi and Luigi F. Agnati


The initiating event in Alzheimer's disease (AD) is an imbalance in the production and clearance of amyloid beta (Aβ) peptides leading to the formation of neurotoxic brain Aβ assemblies. Cerebrospinal Fluid (CSF), which is a continuum of the brain, is an obvious source of markers reflecting central neuropathologic features of brain diseases. In this review, we provide an overview and update on our current understanding of the pathobiology of human CSF Aβ peptides. Specifically, we focused our attention on the heterogeneity of the CSF Aβ world discussing (1) basic research studies and what has been translated to clinical practice, (2) monomers and other soluble circulating Aβ assemblies, and (3) communication modes for Aβ peptides and their microenvironment targets. Finally, we suggest that Aβ peptides as well as other key signals in the central nervous system (CNS), mainly involved in learning and hence plasticity, may have a double-edged sword action on neuron survival and function

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1997). a n dJ .K .T e l l e r ,“ H e t e r o g e n e i t yo fw a t e r - s o l u b l ea m y l o i dβ-peptideinAlzheimer’sdiseaseandDown’ssyndromebrains,”
  2. (1996). a n dJ .Q .T r o j a n o w s k i ,“ F u l l - l e n g t ha m y l o i d - β(1-42(43)) and amino-terminally modified and truncated amyloid-β42(43) deposit in diffuse plaques,”
  3. (2010). A new hypothesis of pathogenesis based on the divorce between mitochondria and their host cells: possible relevance for alzheimer’s disease,”
  4. (2010). A novel abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease,”
  5. (2009). A novel pathway for amyloid precursor protein processing,”
  6. (2002). a r d ya n dD .J .S e l k o e ,“ T h ea m y l o i dh y p o t h e s i so f Alzheimer’s disease: progress and problems on the road to therapeutics,”
  7. (2000). a r i g a y a ,T .C .S a i d o ,C .B .E c k m a n ,C .M .P r a d a
  8. (2006). A specific amyloidβ protein assembly in the brain impairs memory,”
  9. (2009). A specific enzyme-linked immunosorbent assay for measuring β-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer Disease,”
  10. (2008). Accelerated releaseofexosomeassociatedGM1ganglioside(GM1)byendocytic pathway abnormality: another putative pathway for GM1-induced amyloid fibril formation,”
  11. (2000). Age-dependent change in the levels of Aβ40 and Aβ42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Aβ42 to Aβ40 level in cerebrospinal fluid from Alzheimer’s disease patients,”
  12. (2006). Alzheimer’s disease β-amyloid peptides are released in association with exosomes,”
  13. (2001). Amino-terminal modification and tyrosine phosphorylation of carboxy-terminal fragments of the amyloid precursor protein
  14. (2009). Amyloid beta mediates memory formation,”
  15. (2004). Amyloid β peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer’s disease,”
  16. (2008). Amyloid β protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization,”
  17. (2005). Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo,”
  18. (1992). Amyloid β-peptide is produced by cultured cells during normal metabolism,”
  19. (2008). Amyloid-related biomarkers for Alzheimer’s disease,”
  20. (2008). Amyloid-β protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory,”
  21. Amyloid-β42 is associated with cognitive impairment in healthy elderly and subjective cognitive impairment,” Journal of Alzheimer’s Disease,.
  22. (2006). An Alzheimer’s disease-specific β-amyloid fragment signature in cerebrospinal fluid,”
  23. (2000). andH.M.Wisniewski,“Plasmaandcerebrospinalfluidlevels of amyloid β proteins 1-40 and 1- 42 in Alzheimer disease,”
  24. (2007). Aβ oligomers—a decade of discovery,”
  25. (2007). Aβ peptides as one of the crucial volume transmission signals in the trophic unitsandtheirinteractionswithhomocysteine.Physiological implications and relevance for Alzheimer’s disease,”
  26. (2010). Aβ40 oligomers identified as a potential biomarker for the diagnosis of alzheimer’s disease,”
  27. (2010). Biomarkers for Alzheimer’s disease and other forms of dementia: clinical needs, limitations and future aspects,”
  28. (2003). Brain-derived neurotrophic factor/TrkBsignalinginmemoryprocesses,”JournalPharmacological Sciences,
  29. (2010). Can Alzheimer disease be prevented by amyloid-β immunotherapy?”
  30. Cerebrospinal fluid and plasma biomarkers
  31. (2009). Cerebrospinal fluid biomarker signature in alzheimer’s disease neuroimaging initiative subjects,”
  32. (2004). Cerebrospinal fluid profile of amyloid β peptides in patients with Alzheimer’s disease determined by protein biochip technology,”
  33. (2006). Characterization of Abeta11-40/42 peptide deposition in Alzheimer’s disease and young Down’s syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer’s disease,”
  34. (2007). Characterization of amyloid β peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry,” J o u r n a lo fP r o t e o m eR e s e a r c h ,
  35. (1984). Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices
  36. (2011). Cognitive effects of cell-derived and synthetically derived Abeta oligomers,”
  37. (2009). Common key-signals in learning and neurodegeneration: focus on excito-amino acids, β-amyloid peptides and α-synuclein,”
  38. (2002). Conformational Abs recognizing a generic amyloid fibril epitope,”
  39. (2009). CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment,”
  40. (2006). CSF diagnosis of Alzheimer’s disease and dementia with Lewy bodies,”
  41. (2009). Cystatin C is released inassociationwithexosomes:anewtoolofneuronal communication which is unbalanced in Alzheimer’s disease,”
  42. (2009). Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly,”
  43. (2009). Detection of amyloid-β aggregates in body fluids: a suitable method for early diagnosis of Alzheimer’s disease?”
  44. (2007). Detection of amyloid-β oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer,”
  45. (2006). Determination of β-amyloid peptide signaturesincerebrospinalfluidusingimmunoprecipitation-mass spectrometry,”
  46. (1998). Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins,”
  47. (2009). Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer’s amyloid-β
  48. (2007). Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils,”
  49. (2010). Distinct cerebrospinal fluid amyloid peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer’s disease,”
  50. (1995). Dominant and differential deposition of distinct β-amyloid peptide species,
  51. (2002). Fadeeva et al., “Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo,”
  52. Ganglioside GM1-mediated amyloid-beta fibrillogenesis and membrane disruption,”Biochemistry,vol.46,no.7,pp.1913–1924,2007.
  53. (2009). Gustavsson et al., “Effects of γ-secretase inhibition on the amyloid β isoform pattern in a mouse model of Alzheimer’s disease,”
  54. (2005). H.Vanderstichele,G.DeMeyer,N.Andreasenetal.,“Aminotruncated β-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment,”
  55. (2009). Hen or egg? Some thoughts on tunneling nanotubes,”
  56. (2000). High-level neuronal expression of Aβ(1-42) in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation,”
  57. (2010). High-molecularweight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients,” T h eJ o u r n a lt h eF e d e r a t i o no f American Societies for Experimental Biology,
  58. (2002). Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer’s disease and in patients with chronic neuroinflammation,”
  59. I fatti e le induzione nell’odierna istologia del sistema nervoso,” Rivista sperimentale di freniatria e medicina legale delle alienazioni mentali,
  60. (1993). i g o - P e l f r e y
  61. (2005). i ra v a l l e ,M .C a l e r o ,M .T a k a o ,A .E .R o h e r ,B .G h e t t i ,a n d R.Vidal,“Amino-terminallytruncatedAβ peptidespeciesare the main component of cotton wool plaques,”
  62. (1998). i t s c h k e ,R .P r i o r ,M .H a u p t ,a n dD .R i e s n e r ,“ D e t e c t i o n of single amyloid β-protein aggregates in the cerebrospinal fluid of Alzheirner’s patients by fluorescence correlation spectroscopy,”
  63. (2011). Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease,”
  64. (2008). Inhibition of γ-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes,”
  65. (1998). Isoe et al., “Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer’s disease: a study in
  66. (2008). Itinerant exosomes: emerging roles in cell and tissue polarity,”
  67. (2002). K.Liu,R.W.Doms,andV.M.Y.Lee,“Glu11sitecleavageand N-terminally truncated Aβ production upon
  68. (1992). L.F.Agnati,M.Zoli,G.Biagini,andK.Fuxe,“Neuronalplasticity and ageing processes in the frame of the ’Red Queen Theory’,”
  69. (2007). Loyens et al., “Alkalizing drugs induce accumulation of amyloid precursor protein
  70. (1985). M a s t e r s ,G .S i m m s ,N .A .W e i n m a n ,G .M u l t h a u p
  71. (2009). M.SimonsandG.Raposo,“Exosomes—vesicularcarriersfor intercellular communication,” Current Opinion in Cell Biology,
  72. (2009). Markers of Alzheimer’s disease in a population attending a memory clinic,” Alzheimer’s and Dementia,
  73. (2010). Mass spectrometriccharacterizationofbrainamyloidbetaisoform signatures in familial and sporadic Alzheimer’s disease,”
  74. (2011). Mechanisms of amyloid-beta peptide uptake by neurons: the role of lipid rafts and lipid raft-associated proteins,”
  75. (2007). Monoclonal antibodies that target pathological assemblies of Aβ,”
  76. (2005). Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease,”
  77. (2000). Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulindegrading enzyme,”
  78. (2008). Neurotrophic factors in Alzheimer’s disease: role of axonal transport,”
  79. (1998). o c k ,S .G o l o m b o w s k i ,F .M ¨ uller-Spahn et al., “Cerebrospinal fluid levels of amyloid precursor protein and amyloidβ-peptideinAlzheimer’sdiseaseandmajordepression— inversecorrelationwithdementiaseverity,”EuropeanNeurology,
  80. (1994). o w i n g ,A .E .R o h e r ,A .S .W o o d se ta l . ,“ C h e m i c a l characterization of Aβ 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease,”
  81. (2009). Oligomerization partially explains the lowering of
  82. (2010). Optimization protocol for amyloid-β peptides detection in human cerebrospinal fluid using
  83. (2004). Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases,”
  84. (2006). Physiological roles for amyloid β peptides,”
  85. (2007). Prediction of Alzheimer’s disease using the CSF Aβ42/Aβ40 ratio in patients with mild cognitive impairment,” Dementia and Geriatric Cognitive Disorders,
  86. (2009). Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study,”
  87. (1999). Protofibrillar intermediatesofamyloidβ-proteininduceacuteelectrophysiological changes and progressive neurotoxicity in cortical neurons,”
  88. (2008). R.Ghidoni,L.Benussi,andG.Binetti,“Exosomes:theTrojan horses of neurodegeneration,”
  89. R.Ghidoni,V.Albertini,R.Squittietal.,“NovelT719PAβPP mutation unbalances the relative proportion of amyloidβ peptides,”
  90. (2003). R.Kayed,E.Head,J.L.Thompsonetal.,“Commonstructure ofsolubleamyloidoligomersimpliescommonmechanismof pathogenesis,”
  91. (2007). Reduced CSF carboxyterminally truncated Aβ peptides in frontotemporal lobe degenerations,”
  92. (1994). Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging,”
  93. (2007). Research criteria for the diagnosis of Alzheimer’s disease: revising
  94. (2010). Revising the definition of Alzheimer’s disease: a new lexicon,”
  95. (2009). Senescence, apoptosis, and stem cell biology: the rationale for an expanded view of intracrine action,”AmericanJournalofPhysiology,HeartandCirculatory
  96. (2011). Shankar,andD.J.Selkoe,“Solubleaβoligomersinhibitlongterm potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors,”
  97. (2009). Shedding microvesicles: artefacts no more,”
  98. (2010). The Alzheimer’s disease-associated amyloid β-protein is an antimicrobial peptide,”
  99. (2003). The amyloidβ (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer’s disease: evidence of a novel carboxyterminally elongated Aβ peptide,”
  100. (2011). The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease,”
  101. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease,” Alzheimer’s and Dementia,
  102. (1985). The effects of the fibre environment on the paths taken by regenerating optic nerve fibres in
  103. (2005). The role of inflammation in Alzheimer’s disease,”
  104. (2014). Translational outpatient memory clinic working group. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment,”JournalofNeurology,vol.257,no.12,pp.2004–
  105. (2003). Truncated betaamyloid peptide species in pre-clinical Alzheimer’s disease as new targets for the vaccination approach,”
  106. Volume transmission as a key featureofinformationhandlinginthecentralnervoussystem possible new interpretative value of the Turing’s B-type machine,”ProgressinBrainResearch,vol.125,pp.3–19,2000.
  107. (2005). β-amyloid is different in normal aging and in Alzheimer disease,”
  108. (1992). β-Amyloid precursor protein cleavage by a membrane-bound protease,”
  109. (1999). β-Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease
  110. (2008). ε-secretase: reduction of amyloid precursor protein ε-site cleavage in Alzheimer’s disease,”